Cargando…

Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence

BACKGROUND: Patient medication adherence is multidimensional and poses significant concerns to health care professionals. One aspect of adherence is a patient forgetting to take their prescribed medication, which may be improved with reminder packaging (RP). The objective of this analysis was to ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Dupclay, Leon, Eaddy, Michael, Jackson, James, Raju, Aditya, Shim, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422118/
https://www.ncbi.nlm.nih.gov/pubmed/22927746
http://dx.doi.org/10.2147/PPA.S31417
_version_ 1782240993926447104
author Dupclay, Leon
Eaddy, Michael
Jackson, James
Raju, Aditya
Shim, Andrew
author_facet Dupclay, Leon
Eaddy, Michael
Jackson, James
Raju, Aditya
Shim, Andrew
author_sort Dupclay, Leon
collection PubMed
description BACKGROUND: Patient medication adherence is multidimensional and poses significant concerns to health care professionals. One aspect of adherence is a patient forgetting to take their prescribed medication, which may be improved with reminder packaging (RP). The objective of this analysis was to assess the impact of RP on patient adherence to antihypertensive therapy. METHODS: This retrospective, propensity score-matched study evaluated patients switching to a single-pill combination of valsartan-hydrochlorothiazide in RP compared with patients remaining on the combination without reminder packaging (non-RP). Patients receiving combination therapy between April 1, 2009 and July 31, 2010 were eligible for inclusion. Patients were propensity score-matched on baseline adherence and background demographic variables, including comorbidities. Medication possession ratio, proportion of days covered, time to refill, and time to discontinuation were evaluated as primary measures of subsequent adherence and persistence. RESULTS: In a total of 9266 matched patients (4633 participants in both cohorts), adherence was significantly higher in the RP cohort compared with patients in the non-RP cohort (medication possession ratio, RP 80% versus non-RP 73%; proportion of days covered, RP 76% versus non-RP 63%; both P < 0.001). Refill timing was 10 days for RP patients versus 16 days for non-RP patients (P < 0.001). Similar trends were observed with respect to time to discontinuation (RP 196 days, non-RP 174 days; P < 0.001). A higher proportion of RP patients remained on therapy compared with non-RP patients, with patients in the RP group being 17% less likely to discontinue therapy compared with patients in the non-RP group (hazards ratio 0.833; 95% confidence interval 0.793–0.875). CONCLUSION: This real-world assessment of differences in adherence and persistence rates demonstrated that patients receiving RP were more adherent and persistent with their treatment regimens.
format Online
Article
Text
id pubmed-3422118
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-34221182012-08-27 Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence Dupclay, Leon Eaddy, Michael Jackson, James Raju, Aditya Shim, Andrew Patient Prefer Adherence Original Research BACKGROUND: Patient medication adherence is multidimensional and poses significant concerns to health care professionals. One aspect of adherence is a patient forgetting to take their prescribed medication, which may be improved with reminder packaging (RP). The objective of this analysis was to assess the impact of RP on patient adherence to antihypertensive therapy. METHODS: This retrospective, propensity score-matched study evaluated patients switching to a single-pill combination of valsartan-hydrochlorothiazide in RP compared with patients remaining on the combination without reminder packaging (non-RP). Patients receiving combination therapy between April 1, 2009 and July 31, 2010 were eligible for inclusion. Patients were propensity score-matched on baseline adherence and background demographic variables, including comorbidities. Medication possession ratio, proportion of days covered, time to refill, and time to discontinuation were evaluated as primary measures of subsequent adherence and persistence. RESULTS: In a total of 9266 matched patients (4633 participants in both cohorts), adherence was significantly higher in the RP cohort compared with patients in the non-RP cohort (medication possession ratio, RP 80% versus non-RP 73%; proportion of days covered, RP 76% versus non-RP 63%; both P < 0.001). Refill timing was 10 days for RP patients versus 16 days for non-RP patients (P < 0.001). Similar trends were observed with respect to time to discontinuation (RP 196 days, non-RP 174 days; P < 0.001). A higher proportion of RP patients remained on therapy compared with non-RP patients, with patients in the RP group being 17% less likely to discontinue therapy compared with patients in the non-RP group (hazards ratio 0.833; 95% confidence interval 0.793–0.875). CONCLUSION: This real-world assessment of differences in adherence and persistence rates demonstrated that patients receiving RP were more adherent and persistent with their treatment regimens. Dove Medical Press 2012-07-18 /pmc/articles/PMC3422118/ /pubmed/22927746 http://dx.doi.org/10.2147/PPA.S31417 Text en © 2012 Dupclay et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Dupclay, Leon
Eaddy, Michael
Jackson, James
Raju, Aditya
Shim, Andrew
Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence
title Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence
title_full Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence
title_fullStr Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence
title_full_unstemmed Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence
title_short Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence
title_sort real-world impact of reminder packaging on antihypertensive treatment adherence and persistence
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422118/
https://www.ncbi.nlm.nih.gov/pubmed/22927746
http://dx.doi.org/10.2147/PPA.S31417
work_keys_str_mv AT dupclayleon realworldimpactofreminderpackagingonantihypertensivetreatmentadherenceandpersistence
AT eaddymichael realworldimpactofreminderpackagingonantihypertensivetreatmentadherenceandpersistence
AT jacksonjames realworldimpactofreminderpackagingonantihypertensivetreatmentadherenceandpersistence
AT rajuaditya realworldimpactofreminderpackagingonantihypertensivetreatmentadherenceandpersistence
AT shimandrew realworldimpactofreminderpackagingonantihypertensivetreatmentadherenceandpersistence